University of Rhode Island
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From University of Rhode Island
Exelixis Looks To Early-Stage Option Rights As Low-Risk Pipeline Expansion Play
The maker of Cabometyx wants to expand its oncology pipeline via deal-making but is wary of the high attrition rate in cancer. Option deals with Cybrexa and Sairopa may avoid some of that risk.
Brief summaries of recent clinical developments in the device industry, including advances in cell therapy & regenerative medicine, dangers of blood substitutes, and a hypothermia-inducing suit.
Vivant Medical Inc.
Vivant Medical Inc. has developed minimally invasive microwave ablation technology for solid tumors. Vivant believes that its technology---which includes a novel ring-shaped probe--will be faster, safer and more effective than radiofrequency ablation.
- Academic and Research Institutions
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.